Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis
NCT06048588Phase 2Completed
- Sponsor
- Beijing Inno Medicine Co., Ltd.
- Start
- Oct 2023
- Primary completion
- Apr 2025
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of YN001 in Coronary atherosclerosis (CAD), sponsored by Beijing Inno Medicine Co., Ltd.. Started Oct 2023; status: completed.
02
Drugs
YN001
03
Conditions
Coronary atherosclerosis (CAD)
Beyond the preview
Go deeper on NCT06048588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048588.